Issue

Vol. 65 No. 6: Issue 6

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Clinical value of plasma cfDNA concentration and integrity in breast cancer patients

https://doi.org/10.14715/cmb/2019.65.6.11
Yajun Miao
Department of Oncology, the First People's Hospital of Nantong. No.6, Haierxiang North Road, 226001 Nantong, Jiangsu Province, China
Yingrui Fan
Department of Oncology, TaiKang XianLin Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. No.188, Lingshan North Road, Qixia District, 210046 Nanjing, Jiangsu Province, China
Liang Zhang
Department of Oncology, the First People's Hospital of Nantong. No.6, Haierxiang North Road, 226001 Nantong, Jiangsu Province, China
Tingting Ma
Department of Oncology, TaiKang XianLin Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. No.188, Lingshan North Road, Qixia District, 210046 Nanjing, Jiangsu Province, China
Rong Li
Department of Oncology, TaiKang XianLin Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. No.188, Lingshan North Road, Qixia District, 210046 Nanjing, Jiangsu Province, China

Corresponding Author(s) : Rong Li

Cellular and Molecular Biology, Vol. 65 No. 6: Issue 6

Abstract

Breast cancer is a malignant tumor that occurs in the glandular epithelial tissues of the breast. It is one of the most common malignant tumors in women. This study was aimed at investigating the role of cell-free DNA (cfDNA) as a potential biomarker for breast cancer diagnosis. Patients with primary breast cancer (n =110) were enrolled in the experimental group, 95 patients with benign breast tumors were in control group 1, while 90 healthy volunteers were in control group 2. Quantitative PCR was used to determine cfDNA concentration and integrity in each group. The cfDNA levels in different groups and their relationship with clinical features of breast cancer patients were analyzed. Receiver operational curves were established to analyze sensitivity and specificity of cfDNA concentration, cfDNA integrity, CEA, CA125 and CA15-3. The cfDNA concentration and cfDNA integrity of the experimental group were significantly higher than those of control groups 1 and 2. The cfDNA concentration and integrity in plasma of experimental group after chemotherapy were significantly lower than those before chemotherapy. While CEA and CA15-3 expressions were significantly correlated with cfDNA concentration, CA125 expression was significantly correlated with cfDNA integrity. Results from ROC curve analysis showed that the sensitivity and specificity of cfDNA concentration and integrity were higher than those of traditional tumor biomarkers. These results indicate that cfDNA concentration and integrity are significantly higher in primary breast cancer patients than in benign breast tumor patients and healthy people. Thus, cfDNA may serve as a potential biomarker of breast cancer.

Keywords

Breast cancer cfDNA Receiver operational curve qRT-PCR.
Miao, Y., Fan, Y., Zhang, L., Ma, T., & Li, R. (2019). Clinical value of plasma cfDNA concentration and integrity in breast cancer patients. Cellular and Molecular Biology, 65(6), 64–72. https://doi.org/10.14715/cmb/2019.65.6.11
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
  2. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv 2015; 9: 481-491.
  3. Bayo J, Castano MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol 2018; 20: 467-475.
  4. Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci 2014; 15: 9546-9565.
  5. Tang S, Wei L, Sun Y, Zhou F, Zhu S, Yang R, et al. CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis. PLoS One 2016; 11: 0163030.
  6. Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in Breast Cancer: Where Are We and Where Are We Going? Adv Clin Chem 2015; 71: 1-23.
  7. Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta 2017; 470: 51-55.
  8. Zhao S, Mei Y, Wang Y, Zhu J, Zheng G, Ma R. Levels of CEA, CA153, CA199, CA724 and AFP in nipple discharge of breast cancer patients. Int J Clin Exp Med 2015; 8: 20837-20844.
  9. Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer 2017; 116: 501-508.
  10. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22: 4157-4164.
  11. Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis 2017; 8: 3045.
  12. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res 2013; 15: 211.
  13. van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 2008; 1137: 18-26.
  14. Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA. Nat Med 2014; 20: 474-475.
  15. Morozkin ES, Babochkina TI, Vlassov VV, Laktionov PP. The effect of protein transport inhibitors on the production of extracellular DNA. Ann N Y Acad Sci 2008; 1137: 31-35.
  16. Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 2015; 112: 1317-1325.
  17. Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther 2012; 12: 209-215.
  18. Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochim Biophys Acta 2016; 1865: 266-274.
  19. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437.
  20. Babayan A, Pantel K. Advances in liquid biopsy approaches for early detection and monitoring of cancer. Genome Med 2018; 10: 21.
  21. Kamel AM, Teama S, Fawzy A, El Deftar M. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer. Tumour Biol 2016; 37: 7565-7572.
  22. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, et al. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer 2016; 7: 1798-1803.
  23. Yoruker EE, Ozgur E, Keskin M, Dalay N, Holdenrieder S, Gezer U. Assessment of circulating serum DNA integrity in colorectal cancer patients. Anticancer Res 2015; 35: 2435-2440.
  24. Cheng J, Cuk K, Heil J, Golatta M, Schott S, Sohn C, et al. Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence. Oncotarget 2017; 8: 54537-54547.
  25. Lin Z, Neiswender J, Fang B, Ma X, Zhang J, Hu X. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget 2017; 8: 26625-26636.
  26. Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, et al. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res 2016; 18: 129.
  27. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell 2010; 140: 619-630.
  28. Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 2016; 7: 48832-48841.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1163 Download : 610